s
News
Vodis Investor Update

September 21st, 2017, Vancouver, British Columbia – Vodis Pharmaceuticals Inc. (CSE: VP / FSE: 1JV1) (“Vodis” or the “Company”) is pleased to inform investors that it is among the set of applicants to have recently been contacted by Health Canada. The Company’s application to produce cannabis under the ‘Access to Cannabis for Medical Purposes Regulations’ (ACMPR) in Canada is currently in ‘Active Review’. The Company is in the process of upgrading its Delta facility to meet the requirements of the ACMPR, which have changed since the Company’s original application under the ‘Marihuana for Medical Purposes Regulations’ (MMPR). These updates include minor hardware upgrades to its video surveillance and intrusion detection systems and installation of a seed-to-sale tracking system. Vodis plans to select Canadian-made Ample Organics as its seed-to-sale tracking system provider.

Vodis is also pleased to announce that the expansion to its facility in Bellingham, WA, announced March 23, 2017, is approximately 75% complete. This work involved major structural changes to the building to support the construction of a 2nd floor within the facility above previously licensed, unused, canopy space. At present the completed work will allow the Company’s tenant, Premium Cannabis Producers LLC (“PCP”), to double its current production capacity. Upon completion, the facility will support the full 10,000 sq ft of PCP’s Tier 2 license capacity. The Company anticipates the Bellingham expansion to be complete before the end of the year.

This news release shall not constitute an offer to sell or solicitation of an offer to buy the securities in any jurisdiction. The securities will not be and have not been registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or applicable exemption from the registration requirements.

About Vodis Pharmaceuticals Inc.

Vodis is one of North America’s foremost brand names in the medical and recreational marijuana business with operations in both the United States and Canada. Its master grow teams have consistently won or placed at each Canadian competition they have entered with their “VIP” brand. The Company, with facilities in British Columbia and Washington State, is also actively looking into expansion opportunities in other countries and throughout the United States.

For further information, please contact:

Ivan Miliovski, CEO
Vodis Pharmaceuticals Inc.
1-866-210-1420 Ext103

-or- 

Soy Garipoglu
Investor Relations
Vodis Pharmaceuticals Inc.
8788 River Road
Delta, BC V4G 1B4
Contact: 778-990-8985
Email: investorrelations@vodis.ca
Web: www.vodis.ca

Forward-Looking Information: This news release contains certain forward-looking information that reflects the current views and/or expectations of the Company with respect to its performance, business and future events. Forward-looking information is based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the business and the industry and markets in which the Company operates. Statements constituting forward-looking information are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Investors are cautioned that all forward-looking information involves risks and uncertainties, which could cause actual results and events to vary significantly. Accordingly, readers should not place undue reliance on forward-looking information, which is qualified in their entirety by this cautionary statement. There can be no assurance that forward-looking information, or the material factors or assumptions used to develop such forward-looking information, will prove to be accurate. The Company does not undertake any obligations to release publicly any revisions for updating any voluntary forward-looking information, except as required by applicable securities law.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.




Earl Oliver

  • Page 1 of 63